Page 19 - Numinus Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Numinus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into Psychedelic Neurology Numinus Wellness Inc. a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its fiscal third quarter results ended May 31, 2021 . In the third quarter, Numinus maintained a healthy cash position, achieved key milestones in its lab and proprietary portfolio, expanded the clinic network, and continued to advance its basic and clinical … Numinus Wellness Inc. (“Numinus” or...

The initial trial would focus on dosage before expanding into psilocybin treatments for a variety of health conditions. “This is another important step for our commitment to the development of naturally sourced, evidence-based product formulations,” said Optimi chairman of the board JJ Wilson. The information package included the investigational product’s chemical constituents, genotype, and formulation as well as procedures and processes to produce a consistent dosage from psilocybe mushrooms. Optimi will retain 100 per cent ownership of the resulting all-natural psilocybin capsule and...

Sairiyo Therapeutics Inc., for the use of DMT in organ transplantations. When patients undergo an organ transplant, there's a high risk of ischemia-reperfusion injury, a type of injury that can occur when blood rapidly returns to the organ after being restricted by a long period. This can lead to the organ being rejected by the body, as well as other injuries to the patient. Preclinical models of kidney transplantation showed that DMT can be used to mitigate injury caused by ischemia-reperfusion. The treatment still needs to undergo extensive clinical research. “We are the first and only co...

Numinus Wellness ends 2Q with C$28.5M after closing Mindspace Wellbeing acquisition Subsequent to the quarter-end, Numinus completed a $40.25 million financing and raised an additional $1.5 million from warrant exercises, putting its current cash balance at around $65 million The Vancouver-based firm is the first Canadian public company to successfully legally extract psilocybe mushrooms, a feat it achieved during 2Q Numinus Wellness Inc (CVE:NUMI) (OTCMKTS:LKYSF) (FRA:LR23)  saw its cash balance balloon to C$28.5 million after closing a C$17.25 million bought deal, its fiscal 2Q...

Numinus’ new Phase I clinical trial, to be conducted in partnership with  KGK Science, will test out the company’s own naturally derived psilocybin formulation on human subjects. The trial will enroll 14 healthy volunteers and will assess the safety and psychoactive properties of a Psilocybe mushroom formulation extracted at the Numinus Bioscience lab in British Columbia. The company holds a license to cultivate and extract magic mushrooms in Canada. As opposed to most psilocybin clinical trials today, Numinus’ study uses a derivative of natural mushrooms instead of a synthesized ver...